Current use and questions concerning intravesical bladder cancer group for superficial bladder cancer Review uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • BCG Vaccine
  • Cancer Vaccines
  • Carcinoma in Situ
  • Urinary Bladder Neoplasms

abstract

  • Bacille Calmette-Guerin (BCG) is the most effective therapy for CIS of the bladder. Although several series have shown a decrease in recurrence and progression of T1 tumor, this effect is temporary. More than one half of patients with T1 tumors treated with BCG will progress over the longterm. A second course of BCG is indicated after an initial complete response. There is no definitive answer regarding the efficacy of maintenance therapy or the optimum dose of BCG. Randomized trials are needed to address these issues in a more conclusive manner. Phase III trials have shown that mitomycin C can be as effective as BCG in the management of papillary tumors; however, BCG is more effective in patients with CIS and high-risk superficial tumors.

publication date

  • February 19, 2000

Research

keywords

  • Review

Identity

Language

  • eng

PubMed ID

  • 10696252

Additional Document Info

start page

  • 137

end page

  • 46,

volume

  • 27

number

  • 1